Astec LifeSciences Q3 revenue up 33% YoY; CFO resigns, new CFO from April

Cfo ResignedManagement Changes View source PDF Explain this filing

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹572.05

prior close

₹571.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+4.0% vs market

Pesticides & Agrochemicals peers, median of 26sector-0.3%+3.1% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 3.1 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

-0.2

15m

+0.6

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8-1.3+4.0-0.3+3.1

Next day

+4.0+2.4+1.5+1.0+2.9

+6.2+3.8+2.4+1.9+4.2

+13.3+2.7+10.5+2.3+11.0

+12.9+1.9+11.0+1.5+11.5

+10.8+4.6+6.3+2.9+7.9

+7.9+5.1+2.9+3.9+4.0

15d

+9.9+2.1+7.8-1.7+11.6

+9.3-2.1+11.4-6.3+15.7

-5.6-6.4+0.8-13.3+7.7

+25.9+9.5+16.3-3.9+29.7

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astec LifeSciences Q3 FY26 standalone revenue rose 33% YoY to Rs 124.72 cr; net loss narrowed to Rs 15.72 cr from Rs 40.40 cr. Nine month revenue up 11% at Rs 289.52 cr with loss of Rs 73.23 cr. Board noted CFO Mugdha Khare resignation effective March 6, 2026 to pursue outside opportunities. Deepak Ochani, chartered accountant with 11+ years at Godrej Agrovet, appointed CFO from April 1, 2026. Statutory auditors gave unmodified review.

Likely market impact

Smooth CFO transition with successor lined up. Q3 loss narrowed sharply YoY but nine month loss persists; revenue growth encouraging.